Fedratinib, an FDA-approved drug, has been found to revolutionize cell communication in cancer, offering a potential therapeutic avenue. This groundbreaking discovery, made by researchers at the University of Michigan, sheds light on the intricate workings of cell organelles and their interdependence. By screening a library of FDA-approved drugs, the team identified fedratinib's ability to influence ERMCS (endoplasmic reticulum and mitochondria contact sites) formation, a crucial aspect of cellular metabolism. The study reveals that fedratinib inhibits BRD4, a protein controlling DNA transcription, leading to the activation of a transcriptional pathway that induces ERMCS formation. This process is reversible, as removing fedratinib from the cells causes the ERMCS to return to their original state.
The researchers utilized electron microscopy to observe novel structural changes in ERMCS sites, resembling those seen in SARS-CoV-2-infected cells and metastatic melanoma. These findings highlight the dynamic nature of cell organelles and their communication, with approximately 30% of mitochondria exhibiting structural alterations. The study suggests that mitochondria with abundant contact sites are utilized to support specific metabolic pathways, indicating a complex interplay between organelles.
The implications of this research are far-reaching. By understanding the signaling pathway that sustains ERMCS, scientists can gain deeper insights into cellular metabolism and its role in various diseases, including neurodegeneration, obesity, cancer, and diabetes. The study's findings open up new avenues for therapeutic intervention, as fedratinib's ability to influence ERMCS formation could potentially be harnessed to treat these conditions. However, further investigation in mouse models is necessary to fully understand the effects and mechanisms involved.
This discovery underscores the importance of cell communication in cancer and the potential of FDA-approved drugs as therapeutic tools. As Yatrik Shah, Professor of Molecular and Integrative Physiology, notes, "Over the past few decades, researchers have seen that cell organelles work in conjunction and they need to talk to each other to do that. By identifying this signaling pathway, we can better understand how these contact sites are sustained."
In conclusion, the study of fedratinib's impact on ERMCS formation represents a significant advancement in our understanding of cellular metabolism and its role in disease. It highlights the intricate relationships between cell organelles and the potential for therapeutic intervention. As research continues, the implications of this discovery may lead to novel treatments for a range of diseases, emphasizing the importance of exploring the complex world of cellular communication.
